智通财经APP讯，先瑞达医疗-B(06669)发布公告，于2025年11月13日，集团收到中国国家药品监督管理局对冠脉整体交换型球囊扩张导管井翼®的注册批准。井翼®适用于冠状动脉狭窄部位或冠状动脉旁路血管狭窄部位进行球囊扩张，以改善心肌灌注，球囊直径为2.0-5.0mm的型号还适用于支架递送后扩张。井翼®是一款半顺应性球囊扩张导管，凭借其更小的头端通过外径和球囊折叠外径，以及优化的推送系统，实现了卓越的通过性和推送性，能有效应对慢性完全闭塞及严重钙化等复杂病变，其整体交换设计也提升了手术效率与安全性。公司将适时在中国开展营销活动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.